MX2022009677A - Composiciones para el tratamiento de enfermedades oculares. - Google Patents

Composiciones para el tratamiento de enfermedades oculares.

Info

Publication number
MX2022009677A
MX2022009677A MX2022009677A MX2022009677A MX2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A MX 2022009677 A MX2022009677 A MX 2022009677A
Authority
MX
Mexico
Prior art keywords
ocular diseases
edonentan
agent
compositions
treatment
Prior art date
Application number
MX2022009677A
Other languages
English (en)
Inventor
Zhongli Ding
Sevgi Gurkan
David Floyd
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of MX2022009677A publication Critical patent/MX2022009677A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere al descubrimiento de que ciertas enfermedades oculares pueden tratarse utilizando formas cristalinas de edonentan. La forma cristalina específica de edonentan se puede usar sola o en combinación con un agente reductor de la presión intraocular (IOP), un agente neuroprotector o un agente anti-VEGF. El uso de formas cristalinas de edonentan, solo o en combinación con un agente adicional, aumenta la perfusión a la retina o reduce la IOP en ciertas enfermedades oculares y reduce el daño a las células de la retina.
MX2022009677A 2020-02-06 2021-02-03 Composiciones para el tratamiento de enfermedades oculares. MX2022009677A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062971002P 2020-02-06 2020-02-06
US202063010212P 2020-04-15 2020-04-15
PCT/US2021/016414 WO2021158663A1 (en) 2020-02-06 2021-02-03 Compositions for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2022009677A true MX2022009677A (es) 2022-09-09

Family

ID=77200537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009677A MX2022009677A (es) 2020-02-06 2021-02-03 Composiciones para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (2) US11873279B2 (es)
EP (1) EP4100406A4 (es)
JP (1) JP2023512763A (es)
KR (1) KR20220143685A (es)
CN (1) CN115103842A (es)
AU (1) AU2021217358A1 (es)
BR (1) BR112022015579A2 (es)
CA (1) CA3168810A1 (es)
IL (1) IL294873A (es)
MX (1) MX2022009677A (es)
WO (1) WO2021158663A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020373065A1 (en) 2019-10-30 2022-05-26 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
CN115103842A (zh) 2020-02-06 2022-09-23 珀弗斯治疗股份有限公司 用于治疗眼部疾病的组合物
WO2022232588A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CN1489467A (zh) 2001-02-02 2004-04-14 Ĭ��ר���ɷ����޹�˾ 含吡唑并[4,3-d]嘧啶和内皮素受体拮抗剂或者噻吩并嘧啶和内皮素受体拮抗剂的药物制剂
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
WO2010144477A2 (en) 2009-06-12 2010-12-16 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR20130050939A (ko) 2010-04-12 2013-05-16 가부시키가이샤 아루떼꾸 우에노 망막 질환의 치료 방법 및 이를 위한 안과용 조성물
RU2667640C1 (ru) 2013-12-19 2018-09-21 Тассос ГЕОРГИУ Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
WO2016195833A1 (en) 2015-05-29 2016-12-08 Edge Therapeutics, Inc. Compositions and methods for reducing visual loss
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) * 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
EP3654941A1 (en) 2017-07-17 2020-05-27 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
AU2020373065A1 (en) 2019-10-30 2022-05-26 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
CN115103842A (zh) 2020-02-06 2022-09-23 珀弗斯治疗股份有限公司 用于治疗眼部疾病的组合物

Also Published As

Publication number Publication date
EP4100406A1 (en) 2022-12-14
CA3168810A1 (en) 2021-08-12
US20230120974A1 (en) 2023-04-20
JP2023512763A (ja) 2023-03-29
IL294873A (en) 2022-09-01
KR20220143685A (ko) 2022-10-25
BR112022015579A2 (pt) 2022-10-11
CN115103842A (zh) 2022-09-23
EP4100406A4 (en) 2023-07-05
AU2021217358A1 (en) 2022-09-08
WO2021158663A1 (en) 2021-08-12
US11873279B2 (en) 2024-01-16
US20240109876A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
MX2022009677A (es) Composiciones para el tratamiento de enfermedades oculares.
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
Kennedy et al. Selective laser trabeculoplasty: an update
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
EP4302734A3 (en) Ocular delivery systems and methods
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
TW200621236A (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2020010078A (es) Composicion farmaceutica que comprenden timolol.
ZA202108950B (en) Oxymetazoline compositions and methods for treating ocular disorders
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
WO2023192691A3 (en) Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
WO2019054960A3 (en) Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging)
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
JP6653898B1 (ja) 非侵襲的角膜又は強膜強化装置
MX2022012426A (es) Reducir o inhibir el daño ocular mediante la administración de hialuronidasa.
CR20230190A (es) Compuesto degradante en un medicamento
CA3167959A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
WO2007025275A3 (en) Control of induced elevated intraocular pressure
MX2023001950A (es) Compuestos y formulaciones para el tratamiento de enfermedades oftalmicas.
WO2023192828A3 (en) Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
Chen et al. Hyperopic Laser in Situ Keratomileusis to Treat Consecutive Hyperopia after Myopic Lasik-A Case Report